La cinética de la adenosina trifosfato de la creatina quinasa alterada en el miocardio humano hipertrofiado fallido

Craig S Smith1, Paul A Bottomley, Steven P Schulman

  • 1Department of Medicine, Cardiology Division, The Johns Hopkins Hospital, Baltimore, MD 21287-6568, USA. rweiss@jhmi.edu

Circulation
|September 6, 2006
PubMed
Resumen

En pacientes con hipertrofia ventricular izquierda (LVH), el deterioro de la cinética de rotación de adenosina trifosfato (ATP) a través de la creatina quinasa (CK) es un factor clave en la progresión hacia la insuficiencia cardíaca crónica (ICC). Este déficit de energía, no los niveles de metabolitos, distingue a los corazones hipertróficos fallidos de los no fallidos.

Videos de Conceptos Relacionados

Muscle Recovery and Fatigue01:24

Muscle Recovery and Fatigue

Muscle fatigue refers to the decline in a muscle's ability to maintain the force of contraction after prolonged activity. It primarily stems from changes within muscle fibers. Even before experiencing muscle fatigue, one may feel tired and have the urge to stop the activity. This response, known as central fatigue, occurs due to changes in the central nervous system, namely the brain and spinal cord. While there is no single mechanism that induces fatigue, it may serve as a protective response...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...